Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never start, stop, or change any medication without direct guidance from your prescribing healthcare provider.

SGLT2 Inhibitors: How They Work for Diabetes

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed the treatment of type 2 diabetes by providing glucose lowering along with cardiovascular and kidney protection. These medications work through a unique mechanism that is independent of insulin, making them a valuable addition to diabetes therapy at nearly any stage of the disease. The ADA now considers SGLT2 inhibitors a fundamental element of cardiovascular and kidney risk reduction in people with type 2 diabetes.

How SGLT2 Inhibitors Work

The kidneys filter approximately 180 grams of glucose from the blood every day. In healthy individuals, nearly all of this glucose is reabsorbed back into the bloodstream through SGLT2 transporters in the proximal renal tubules. SGLT2 inhibitors block this reabsorption, causing excess glucose to be excreted in the urine.

This mechanism produces several effects:

Blood glucose reduction without stimulating insulin secretion
Weight loss of approximately 1 to 4 kg (the excreted glucose represents lost calories)
Blood pressure reduction of 1.7 to 6.9 mmHg systolic and 0.9 to 3.5 mmHg diastolic (through mild osmotic diuresis and natriuresis)
Reduced intraglomerular pressure in the kidneys, which slows diabetic kidney disease progression

Because the mechanism is insulin-independent, SGLT2 inhibitors work at any stage of type 2 diabetes, whether the patient still produces significant insulin or not.

Available SGLT2 Inhibitors

Medication	Brand Name	Approved Indications	Typical Dose
Empagliflozin	Jardiance	Type 2 diabetes, heart failure (HFrEF and HFpEF), CKD	10–25 mg daily
Dapagliflozin	Farxiga	Type 2 diabetes, heart failure, CKD	5–10 mg daily
Canagliflozin	Invokana	Type 2 diabetes, diabetic kidney disease	100–300 mg daily
Ertugliflozin	Steglatro	Type 2 diabetes	5–15 mg daily

Empagliflozin and dapagliflozin have the broadest evidence base, with approved indications extending to heart failure and chronic kidney disease independently of diabetes status.

Cardiovascular and Kidney Benefits

The cardio-renal benefits of SGLT2 inhibitors have been demonstrated in multiple large-scale outcome trials and represent the primary reason these drugs are now recommended so early in type 2 diabetes treatment.

Heart

EMPA-REG OUTCOME (empagliflozin): 14% reduction in major adverse cardiovascular events; 35% reduction in heart failure hospitalization; 32% reduction in cardiovascular death.
DECLARE-TIMI 58 (dapagliflozin): Significant reduction in cardiovascular death and heart failure hospitalization.
Heart failure: Both empagliflozin and dapagliflozin are now approved for heart failure (both reduced and preserved ejection fraction), regardless of diabetes status.

Kidney

CREDENCE (canagliflozin): 30% reduction in the risk of kidney failure, dialysis, transplant, or renal death.
DAPA-CKD (dapagliflozin): 39% reduction in the composite of sustained decline in eGFR, kidney failure, or renal/cardiovascular death.
EMPA-KIDNEY (empagliflozin): Significant reduction in kidney disease progression or cardiovascular death.

The 2026 ADA Standards consider SGLT2 inhibitors a fundamental element of risk reduction alongside GLP-1 receptor agonists. For patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors are recommended regardless of A1C level.

For cardiovascular context, see Diabetes and Heart Disease: Reducing Your Risk. For kidney-related information, see Diabetic Nephropathy: Kidney Health and Diabetes.

Side Effects and Safety

Common

Genital yeast infections (mycotic infections): The most common side effect, affecting 5%–10% of patients. Excess glucose in the urine creates a favorable environment for yeast. Good hygiene and prompt treatment with antifungals manage this.
Urinary tract infections: Slightly increased risk, though less common than genital infections.
Increased urination and thirst: Expected pharmacologic effect from glucose and fluid excretion.

Less Common but Serious

Volume depletion/dehydration: Particularly in older adults, those taking diuretics, or during hot weather. Stay well hydrated.
Euglycemic diabetic ketoacidosis (DKA): A rare but dangerous condition where ketoacidosis occurs at normal or near-normal blood sugar levels. Risk factors include illness, surgery, fasting, excessive alcohol, or very low carbohydrate intake. Know the symptoms: nausea, vomiting, abdominal pain, fatigue, and difficulty breathing. Seek emergency care immediately.
Fournier’s gangrene: Extremely rare necrotizing fasciitis of the perineum. Seek immediate medical attention for severe pain, tenderness, or swelling in the genital/perineal area with fever.
Lower extremity amputations: An increased risk was observed with canagliflozin in the CANVAS trial (6.3 vs. 3.4 per 1,000 patient-years). This signal has not been consistently observed with other SGLT2 inhibitors.

Who Should Avoid SGLT2 Inhibitors

Patients with type 1 diabetes (high DKA risk; not approved for this indication)
Patients with severe kidney impairment (eGFR below 20 mL/min; check specific drug thresholds)
Patients with frequent urinary or genital infections

SGLT2 Inhibitors in Combination Therapy

SGLT2 inhibitors are commonly combined with:

Combination	Rationale
Metformin + SGLT2i	Complementary mechanisms; metformin reduces liver output, SGLT2i reduces renal reabsorption
GLP-1 RA + SGLT2i	Additive glucose lowering, weight loss, and cardio-renal protection
Insulin + SGLT2i	SGLT2i reduces insulin requirements and mitigates insulin-associated weight gain

For more on metformin, see Metformin: What Every Diabetic Should Know. For GLP-1 agonists, see GLP-1 Medications: Ozempic, Mounjaro, and Beyond.

Key Takeaways

SGLT2 inhibitors lower blood sugar by blocking glucose reabsorption in the kidneys, an insulin-independent mechanism that also reduces weight and blood pressure.
The primary clinical value of SGLT2 inhibitors lies in their proven cardiovascular and kidney protection, demonstrated in multiple large outcome trials.
The 2026 ADA Standards recommend SGLT2 inhibitors for patients with type 2 diabetes and cardiovascular disease, heart failure, or chronic kidney disease regardless of A1C.
Common side effects include genital yeast infections and increased urination; rare but serious risks include euglycemic DKA.
These medications are prescription-only and should be initiated and monitored by your healthcare provider as part of a comprehensive diabetes treatment plan.

Sources

American Diabetes Association. “9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care — 2026.” Diabetes Care, 49(Supplement_1), January 2026. diabetes.org
National Center for Biotechnology Information. “SGLT2 Inhibitors: Pharmacology and Clinical Applications.” StatPearls, updated 2025. ncbi.nlm.nih.gov
Zinman B, et al. “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME).” NEJM, 2015.

This article is part of the MDTalks Diabetes Hub. For comprehensive management, see the Complete Guide to Diabetes Management in 2026.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Never change your medication without consulting your healthcare provider.